A Review of Fluoroquinolones with a Focus on Veterinary-Approved Agents
Abstract
Fluoroquinolones are broad-spectrum, bactericidal antibacterial agents used in both human and veterinary medicine. Some human-approved drugs are used off label in veterinary medicine while veterinary-approved drugs are not used in humans. Veterinary-approved fluoroquinolones are used on both food and companion animals and against a wide range of clinical indications including infections of the urinary tract, respiratory tract, skin and skin structure, mammary gland and others. Not all veterinary-approved fluoroquinolones have the same clinical indication and it is important to understand these important differences. A recently approved for food animals agent called pradofloxacin is characterized as being dual targeting in that it simultaneously inhibits DNA gyrase (topoisomerase II) and Topoisomerase IV-two enzymes critical for DNA replication. Simultaneous targeting of two enzymes is argued to reduce the likelihood for resistance selection. This article reviews veterinary-approved fluoroquinolones including an overview of the drugs, in vitro activity including bactericidal properties, pharmacokinetic/pharmacodynamics, antimicrobial resistance, anti-inflammatory properties and clinical trial results. Appropriate use of this important class of antimicrobial agents is essential for clinical success and long-term viability of these compounds.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.